Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Dimension Therapeutics, Inc. | dmtx-ex312_204.htm |
| EX-31.1 - EX-31.1 - Dimension Therapeutics, Inc. | dmtx-ex311_205.htm |
| 10-Q - 10-Q - Dimension Therapeutics, Inc. | dmtx-10q_20170930.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Dimension Therapeutics, Inc. (the “Company”) for the period ended September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, that to her knowledge:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Date: November 6, 2017 |
By: |
/s/ Annalisa Jenkins |
|
|
|
Annalisa Jenkins |
|
|
|
President and Chief Executive Officer |
|
|
|
(Principal Executive Officer) |
|
|
|
|
|
Date: November 6, 2017 |
By: |
/s/ Mary Thistle |
|
|
|
Mary Thistle |
|
|
|
Chief Operating Officer |
|
|
|
(Principal Financial Officer) |